3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Breast Neoplasms
7
Endometrial Neoplasms
5
Neoplasms
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Metastatic Castration-resistant Prostate Cancer
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Interventions
Cyclophosphamide
3
fludarabine
2
Paclitaxel
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
olaparib
1
niraparib
1
mirvetuximab soravtansine
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
Tinzaparin
1
Propranolol
1
Palliative Care
1
Nivolumab
1
Neoadjuvant Therapy
1
Music Therapy
1
Losartan
1
Indocyanine Green
1
GEN-1
1
Etodolac
1
E7777 fusion protein
1
Clarithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
olaparib
×
30 days
×
Clear all
NCT06915025
2026-06-02
OVATION-3
Imunon
Phase 3
Recruiting
500 enrolled